Johnson & Johnson Partners with Trump Administration to Lower Drug Costs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16h ago
0mins
Source: Businesswire
- Lower Drug Costs: Johnson & Johnson has reached a voluntary agreement with the Trump Administration aimed at improving access to medicines and lowering costs for millions of American patients, demonstrating the potential of public-private collaboration and expected to significantly enhance patient quality of life.
- Massive Investment Commitment: The company is committed to a $55 billion investment in U.S. manufacturing, research, and technology by 2029, having initiated billions in investments over the past 10 months to support its goal of producing the majority of advanced medicines domestically.
- New Facility Construction: As part of the $55 billion investment, Johnson & Johnson is announcing the establishment of two new manufacturing facilities in Pennsylvania and North Carolina, which are expected to create approximately 5,000 skilled manufacturing and construction jobs, further driving local economic growth.
- Biopharmaceutical Expansion: The new biopharmaceutical manufacturing site in North Carolina will create around 120 new jobs, with the $2 billion investment being phased in over the next decade, reflecting the company's long-term commitment to the U.S. market.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 205.750
Low
176.00
Averages
207.26
High
230.00
Current: 205.750
Low
176.00
Averages
207.26
High
230.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
